Alnylam Pharmaceuticals
ALNY
#650
Rank
โ‚น3.677 T
Marketcap
โ‚น27,546
Share price
-0.61%
Change (1 day)
-1.15%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Cash on Hand

Cash on Hand as of March 2026 : โ‚น284.49 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company has โ‚น284.49 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Alnylam Pharmaceuticals - Cash on Hand chart (from 2003 to 2026)

Cash on Hand by year

Year Cash on Hand Change
2025-12-31โ‚น261.09 B12.95%
2024-12-31โ‚น231.15 B13.83%
2023-12-31โ‚น203.07 B11.94%
2022-12-31โ‚น181.42 B0.08%
2021-12-31โ‚น181.28 B32.24%
2020-12-31โ‚น137.08 B25.14%
2019-12-31โ‚น109.54 B44.51%
2018-12-31โ‚น75.80 B-29.77%
2017-12-31โ‚น107.94 B153.43%
2016-12-31โ‚น42.59 B-40.68%
2015-12-31โ‚น71.80 B62.62%
2014-12-31โ‚น44.15 B190.69%
2013-12-31โ‚น15.18 B125.89%
2012-12-31โ‚น6.72 B-13.17%
2011-12-31โ‚น7.74 B-25.86%
2010-12-31โ‚น10.44 B-19.99%
2009-12-31โ‚น13.05 B-36.88%
2008-12-31โ‚น20.68 B35.18%
2007-12-31โ‚น15.30 B59.04%
2006-12-31โ‚น9.62 B167.28%
2005-12-31โ‚น3.60 B80.53%
2004-12-31โ‚น1.99 B88.84%
2003-12-31โ‚น1.05 B42.28%
2002-12-31โ‚น0.74 B

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
Novartis
NVS
โ‚น659.60 B 131.85%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚น606.63 B 113.24%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
โ‚น827.57 B 190.90%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
โ‚น61.75 B-78.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
โ‚น6.17 B-97.83%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
โ‚น34.89 B-87.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚น353.67 B 24.32%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
โ‚น168.66 B-40.71%๐Ÿ‡บ๐Ÿ‡ธ USA